GBT Technologies Inc. received a notice of allowance and expected to be granted in the next upcoming months. qTerm non-provisional patent was filed on August 3, 2020, application #16/983,289 and covers an electronic health device to measure human vitals with a touch of a finger, internal project name qTerm. GBT completed the development of a fully working prototype in 2022 including robust testing, debugging and participant's study.

qTerm's first release is planned to include body temperature, blood oxygen and heart rate vitals. The second release is planned to include blood pressure measurement and enhanced, AI-driven analytics support. The device is accompanied by a smartphone mobile app and synchronized web application to keep measurements history and provide analytics for user's records at a later phase.

The web and mobile applications will enable a direct access to the user's data anywhere around the world including geographical location, statistical and personal information, making it an efficient, remote telemedicine technology. Upon user's permission, user's body temperature and location can be anonymously shared with other users to provide health risk proximity alerts. GBT plans to expand its IP protection for qTerm, further adding advanced AI systems and methods concepts in the near future.

There is no guarantee that the Company will be successful in researching, developing or implementing this system. In order to successfully implement this concept, the Company will need to raise adequate capital to support its research and, if successfully researched, developed and granted regulatory approval, the Company would need to enter into a strategic relationship with a third party that has experience in manufacturing, selling and distributing this product. There is no guarantee that the Company will be successful in any or all of these critical steps.